Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 9/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 8/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | PTGES | O14684 | 1/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.78 |
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | PDE5A | O76074 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.78 |
| ▸ | CA2 | P00918 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CA3 | P07451 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430302 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL981158 | 0.99 | PDPK1 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6342351 | 0.94 | PTGS2 (0.90) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL980960 | 0.92 | PDPK1 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL3243739 | 0.91 | PTGS2 (0.84) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6013890 | 0.91 | PTGS2 (0.84) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL3243753 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6343023 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL3246379 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Mavacoxib SCHEMBL212699 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351850-B2 | Methods of producing full-length antibodies using E. coli | SUTRO BIOPHARMA, INC. (US) | 2025-07-08 | — | — | US | claimed |
| US-20250188169-A1 | METHOD FOR TREATING CLONAL HEMATOPOIETIC BLOOD DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-12 | — | — | US | claimed |
| EP-3917908-B1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | COUNCIL SCIENT IND RES (IN) | 2024-08-14 | — | — | EP | claimed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | claimed |
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | claimed |
| WO-2023192969-A1 | METHOD FOR TREATING CLONAL HEMATOPOIETIC BLOOD DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023075715-A1 | A PHARMACEUTICAL FORMULATION INCLUDING LEUKOTRIENE RECEPTOR ANTAGONISTS AND/OR LEUKOTRIENE SYNTHESIS INHIBITORS COMBINED WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-05-04 | — | — | WO | claimed |
| EP-4143233-A1 | METHODS OF PRODUCING FULL-LENGTH ANTIBODIES USING E.COLI | Sutro Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | claimed |
| US-11559517-B2 | Promotion of epithelial repair | TELETHON KIDS INSTITUTE (AU) | 2023-01-24 | — | — | US | claimed |
| WO-1998016227-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1998-04-23 | — | — | WO | claimed |
| WO-1997029775-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997029774-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | claimed |
| US-5563165-A | PROSTAGLANDIN INHIBITOR; FDA ORANGE BOOK LISTED PATENT FOR CELEBREX | G. D. SEARL & CO. (US) | 1996-10-08 | — | — | US | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | PTGS2 449/4885PTGS1 347/4885PDPK1 1297/4885 |
| US-12351850-B2 | Methods of producing full-length antibodies using E. coli | MRPL21, TXNRD1, PRDX3 | PTGS2 1501/4885PTGS1 1514/4885PDPK1 4141/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | PTGS2 449/4885PTGS1 347/4885PDPK1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.